Taisho Pharmaceutical Pabron Gold A (Granules) unlicensed product:, product is labelled to contain dihydrocodeine phosphate that is listed on Schedule I of the CDSA
Brand(s)
Last updated
Summary
Product
Taisho Pharmaceutical Pabron Gold A (Granules)
Issue
Health products - Product safety
What to do
Consult your health care professional if you have any health concerns.
Affected products
| Brand Product Name | Product Name | Market Authorization | Dosage Form | Strength | Lot |
|---|---|---|---|---|---|
| Taisho Pharmaceutical Pabron Gold A | Taisho Pharmaceutical Pabron Gold A | No market authorization | Granules | Guaifenesin 60 mg, Dihydrocodeine phosophate 8 mg, dl-Methylephedrine Hydrochloride 20 mg, Acetaminophen 300 mg, Chlorpheniramine Maleate 2.5 mg, Anhydrous Caffeine 25 mg, Riboflavin 4 mg | All |
Issue
Product sold without market authorization (DIN) in Canada. Product is labelled to contain dihydrocodeine phosphate that is listed on Schedule I of the Controlled Drugs and Substances Act. Product is labelled to contain guaifenesin, dl-methylephedrine hydrochloride, acetaminophen, chlorpheniramine maleate and caffeine that may pose a risk to health.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Roope International Trading Ltd.
118-21300 Gordon Way,
Richmond, BC
V6W 1J8
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type II
Identification number
RA-75652
Get notified
Receive emails about new and updated recall and safety alerts.